Oncolytics Biotech Inc. (TSE:ONC – Get Free Report) shares hit a new 52-week low during mid-day trading on Friday . The stock traded as low as C$0.86 and last traded at C$0.88, with a volume of 6500 shares changing hands. The stock had previously closed at C$0.90.
Oncolytics Biotech Stock Performance
The company has a market cap of C$66.28 million, a PE ratio of -2.40 and a beta of 1.35. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The stock’s 50-day simple moving average is C$1.02 and its 200 day simple moving average is C$1.27.
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Read More
- Five stocks we like better than Oncolytics Biotech
- The Significance of Brokerage Rankings in Stock Selection
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Which Wall Street Analysts are the Most Accurate?
- JPMorgan: The ‘NVIDIA of Banking’ Poised for More Gains?
- How to Capture the Benefits of Dividend Increases
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
